Posters & Publications


AACR 2018: The allosteric inhibitor of CD44v6 AMC303 blocks c-MET, RON and VEGFR-2 dependent signaling and cellular processes


First-in-Human Study of AMC303 as Monotherapy in Patients with Advanced and Solid Tumors of Epithelial Origin


AACR 2017: Allosteric inhibition of the Receptor Tyrosine Kinases c-MET, RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound AMC303

Related publications

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V., Gastroenterology. 2016 Feb;150(2):513-25. Epub 2015 Oct 24.

CD44, a therapeutic target for metastasising tumours. Orian-Rousseau V., Eur J Cancer. 2010 May;46(7):1271-7. Epub 2010 Mar 19. Review.

A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Héroult M, Augustin HG, Ponta H, Orian-Rousseau V., Blood. 2009 Dec 10;114(25):5236-44. Epub .

Involvement of CD44v6 in InlB-dependent Listeria invasion. Jung C, Matzke A, Niemann HH, Schwerk C, Tenenbaum T, Orian-Rousseau V., Mol Microbiol. 2009 Jun;72(5):1196-207. Epub 2009 Apr 30.

A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Matzke A, Herrlich P, Ponta H, Orian-Rousseau V., Cancer Res. 2005 Jul 15;65(14):6105-10.

CD44 is required for two consecutive steps in HGF/c-Met signaling. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. Genes Dev. 2002 Dec 1;16(23):3074-86.

Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Sleeman JP, Arming S, Moll JF, Hekele A, Rudy W, Sherman LS, Kreil G, Ponta H, Herrlich P. Cancer Res. 1996 Jul 1;56(13):3134-41.

CD44: structure, function, and association with the malignant process. Naor D, Sionov RV, Ish-Shalom D. Adv Cancer Res. 1997;71:241-319.

CD44 splice variants as prognostic markers in colorectal cancer. Wielenga VJ, van der Voort R, Mulder JW, Kruyt PM, Weidema WF, Oosting J, Seldenrijk CA, van Krimpen C, Offerhaus GJ, Pals ST. Scand J Gastroenterol. 1998 Jan;33(1):82-7.

A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Haußmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, P. (1991). Cell 65, 13-24.